Krabbe Disease (KD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Krabbe Disease (KD) is a neurodegenerative disorder inherited in an autosomal recessive pattern, stemming from a deficiency in the lysosomal enzyme galactocerebrosidase. The responsible gene, GALC, is located on chromosome 14q31.3. Typical symptoms of the “early infantile” or “early onset” form of KD include feeding difficulties, hyperirritability, periodic fever of unknown origin, psychomotor regression, and convulsive seizures. The ophthalmological examination may reveal macular cherry red spots. As the disease progresses, patients enter a stage known as “burnout,” characterized by blindness, muscle weakness, and loss of voluntary movements, with some experiencing microcephaly or macrocephaly depending on disease progression. Manifestations occur at various ages: 10% of cases present between 7–12 months, 22% between 13 months and 10 years, and 5% manifest in adolescence or adulthood. KD is categorized into four clinical subtypes based on the age of onset.

Thelansis’s “Krabbe Disease (KD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Krabbe Disease (KD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Krabbe Disease (KD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Krabbe Disease (KD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Krabbe Disease (KD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Krabbe Disease (KD), Krabbe Disease (KD) market outlook, Krabbe Disease (KD) competitive landscape, Krabbe Disease (KD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)